Frontlight ResearchEarly access
Taking people in South KoreaNo phase
Observing a combined blood pressure pill in Korean people with hypertension
Observes amlodipine, losartan and chlorthalidone in Korean people with hypertension.
Key facts
- Who runs it
- Hanmi Pharmaceutical Company Limited
- Where
- Gyeonggi-do, South KoreaSee the site
- Trial code
- Registry title
- Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension
- Status
- Recruiting
- People taking part
- 3,500 people, planned
- Started
- 19 Mar 2026
- Expected to end
- 31 Aug 2028
- Type of study
- Observational
- Treatments tested
- AMOPREL TAB 1.67/16.67/4.17mg
- Record updated
- 25 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for Korean adults with high blood pressure, either newly diagnosed or taking one blood pressure drug, whose doctor has decided to give Amoprel tablets.
- Age
- 19 years or older
- Sex
- All sexes can join.
- Disease stage
- High blood pressure (hypertension), newly diagnosed or currently treated with a single blood pressure drug.
- Earlier treatment
- People already on blood pressure treatment must be taking only one blood pressure drug.
Main reasons for not taking part
- Has a reason that rules out Amoprel Tab. or Amozartan Plus Tab. listed in their usage precautions
- Pregnant, possibly pregnant, or breastfeeding
- Currently taking part in an interventional study
- The researcher judges the person not fit to take part for other reasons
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Korean patients aged 19 years or older diagnosed with hypertension
- Individuals newly diagnosed with hypertension or currently taking a single antihypertensive drug
- Individuals for whom administration of Amoprel tablets has been determined based on the researcher's medical judgment
- Individuals who have heard an explanation of this study and have voluntarily given written consent to participate in the study
Who cannot take part
- Individuals falling under the contraindications listed in the precautions for use of Amoprel Tab. or Amozartan Plus Tab
- Pregnant women, women who may be pregnant, and nursing mothers
- Individuals currently participating in an interventional study
- Individuals deemed unsuitable for participation in this study by the researcher for other reasons
Where in South Korea
- Yongin Severance HospitalGyeonggi-do, South KoreaContact: PMTaking people
About the trial
What the trial wants to find out
A multicenter, prospective, non-interventional, observational study to evaluate effectiveness and safety of sequential triple combination therapy (amlodipine/losartan/chlorthalidone) in Korean patients with hypertension
Treatments tested
- AMOPREL TAB 1.67/16.67/4.17mg
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Prospective, Non-interventional, Observational Study to Evaluate Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension
- Plain-language title
- Observing a combined blood pressure pill in Korean people with hypertensionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 25 August 2026